Results from the COAPT study continue to roll in, and it was all positive news for the MitraClip team at the TCT conference in San Francisco this month.

Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

Researchers on the International Space Station are leveraging the microgravity conditions within the ISS U.S. National Laboratory to study heart cells in ways we can’t on the ground.

A commonly prescribed drug used to treat attention-deficit/hyperactivity disorder (ADHD) disproportionately affects the development of children’s brains compared to adults with ADHD, according to a new study published in Radiology.

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent. 

Ambra Health, makers of the leading cloud-based, medical image management suite, today announced a new collaboration with Google Cloud to advance healthcare research with anonymized medical imaging data.

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.